BioPharma Dive December 2, 2021
Jacob Bell

Dive Brief:

  • GlaxoSmithKline and the University of Oxford are creating a new center meant to develop medicines faster and at a higher success rate, with an initial focus on diseases of the brain such as Alzheimer’s, Parkinson’s and ALS.
  • The Oxford-GSK Institute of Molecular and Computational Medicine will be based at the university and come equipped with 30 million pounds, or roughly $40 million, in funding from the drugmaker. According to the partners, the institute will use genomic data, machine learning and other technologies to better understand how diseases work and design new treatments for them.
  • Additionally, the institute wants to have some evidence earlier in the research and development process that its medicines work as intended. To help...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article